Overview of Исла-Минт

Quick Facts

Property	Description
Active ingredient	Cetraria islandica (Iceland Moos) Extract
Form	Pastille / Lozenge
Pharmacological class	Traditional Herbal Medicinal Product (THMP), Demulcent
Common use	Symptomatic relief of throat and mouth irritation
Origin	Natural, Herbal

What Type of Medicine is Исла-Минт? (Identity and Classification)

Исла-Минт is defined as a Traditional Herbal Medicinal Product (THMP) belonging to the demulcent pharmacological class, designed for the symptomatic relief of irritations in the throat and mouth. Preparations containing the Iceland Moos thallus are used for alleviating irritation of the pharyngeal mucosa associated with dry cough. This supports the product's primary role in soothing and reducing discomfort, which is recognized as beneficial for individuals with strained vocal cords. The product is administered via the oromucosal route in the form of a solid, mint-flavored pastille or lozenge.

Composition: Iceland Moos (Cetraria islandica) Extract

The active ingredient is the aqueous thick extract derived from Iceland Moos (Cetraria islandica), a lichen that underpins the product's phytopharmaceutical nature. The mechanical action stems from the high concentration of mucilage substances, specifically the polysaccharides like lichenin, found within the extract. The viscous properties of Cetraria islandica extracts are due to this mucilage content, allowing them to form protective gels. The pastille form is a differentiating factor, engineered to ensure the slow and sustained release of the mucilage, maximizing contact time with the irritated mucosa.

How the Mucilage Provides Soothing Relief (High-Level Mechanism)

The mechanism of relief is primarily physical, delivered by the dissolved mucilage components that act as an enveloping agent to form a thin, protective film over the irritated mucous membranes. This layer physically shields the delicate lining of the mouth and throat from external irritants, such as dust or dry air. This mechanism provides a direct soothing action effective for relieving the resulting discomfort, persistent tickling, hoarseness, and minor irritation that leads to dry coughs, a typical use scenario.

Regulatory References

EMA Monograph on Iceland Moss

What side effects are possible with Исла-Минт?

Possible Side Effects and Safety Information

The safety profile for preparations containing Iceland Moos (Cetraria islandica) extract, a Traditional Herbal Medicinal Product, indicates a notably low risk based on official regulatory reviews.

Documented Adverse Reactions and Frequency

Official regulatory documents state that there are no known undesirable effects reported at the time of the EMA assessment for its approved traditional uses. As a result, the frequency for any adverse effect is officially classified as not known due to the absence of sufficient data from reported cases. The focus of the regulatory safety profile is on defined limitations and contraindications rather than specific adverse reaction listings.

Contraindications and Safety Limitations

Safety Constraint	Regulatory Statement
Primary Contraindication	Hypersensitivity (allergy) to the active substance (Cetraria islandica extract) or to any of the excipients.
Drug Absorption	The mucilage content may cause the delayed absorption of concomitantly administered medicines due to its physical, film-forming action.

Safety for Special Populations

Specific usage limitations are documented for certain patient groups where safety has not been fully established or the formulation presents a risk:

Pregnancy and Lactation: Use is not recommended due to the absence of sufficient regulatory safety data for these periods.
Pediatrics: Use is not recommended in children under 6 years of age. This restriction is primarily related to the pharmaceutical form (solid pastille) and the potential choking risk in this age group, rather than the ingredient itself.

High-Level Safety Note

Regulatory documents include a cautionary note that if symptoms such as dyspnoea (difficulty breathing), fever, or purulent sputum occur, medical consultation is necessary to rule out underlying conditions. This is a safety measure to ensure serious illness is not mistakenly managed solely with symptomatic relief.

Overdose and Emergency Response

The official overdose profile for the Traditional Herbal Medicinal Product containing Iceland Moos Extract is defined by its low risk of acute systemic toxicity. Authoritative regulatory documents, such as the European Medicines Agency (EMA) monograph, explicitly state that no case of overdose has been reported for the preparation since its authorization. This regulatory position confirms an absence of formally documented clinical manifestations or severe, life-threatening outcomes specifically associated with excessive ingestion.

Overdose Factor	Official Regulatory Status
Documented Manifestations	No case of overdose has been reported.
Systemic Risk	No severe systemic outcomes documented.
Specific Antidote	No specific antidote is known.

When to Seek Help

The regulatory guidance for managing a potential, theoretical over-ingestion is restricted to symptomatic and supportive treatment. This non-specific approach is consistent with the product's purely physical, demulcent action on mucous membranes.

Official documentation mandates that users must consult a healthcare professional if severe or persistent symptoms, such as the appearance of fever or difficulty breathing, occur during use. These serious manifestations require independent medical evaluation and are not listed as direct outcomes of the product’s overdose. The official profile does not list any population-specific considerations for overdose severity.

Therapeutic Uses of Исла-Минт

What Исла-Минт Treats: Main Uses and Benefits

Symptomatic Relief for Dry and Irritative Cough

The primary role of this traditional herbal medicinal product is to offer supportive local relief for symptoms related to irritation and dryness in the upper respiratory tract. The traditional use of Iceland moss is established for the symptomatic treatment of oral or pharyngeal irritation and associated dry cough. This is generally applied across conditions presenting with acute or episodic changes in mucosal comfort.

The medication is commonly used for managing symptom clusters such as dry, non-productive cough and the associated tickling sensation, as well as providing support for hoarseness and acute pharyngeal dryness. It is applicable in contexts such as vocal strain from prolonged speaking and managing irritation linked to environmental factors like dust or dry air. The general benefit is that it helps ease the overall symptom load, which may assist with preserving comfort during periods of symptomatic strain and supports the patient during difficult episodes by easing distress related to voice comfort.

“The benefit provided is local, supportive relief, assisting the patient during difficult episodes of irritation and dryness.”

Quick Fact: Relief for Irritative Cough
Symptom Management Focus	Dry, irritative cough and tickling sensation
Common Use Context	Episodes of vocal strain or exposure to dry/dusty air
Main Patient Benefit	Supports easing of overall symptom load and discomfort

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Исла-Минт

The eligibility profile for this Iceland Moos extract pastille is defined by official regulatory documentation, primarily the European Medicines Agency (EMA) Monograph, which establishes rules for both permitted and restricted use.

Eligibility Scope

Classification	Population Group	Regulatory Status
Allowed Populations	Adults, Adolescents, and the Elderly	Permitted
	Children mathbf6 to mathbf12 years of age	Permitted
Contraindicated Populations	Patients with Hypersensitivity to Cetraria islandica extract	Absolute Contraindication
Not Recommended	Children under mathbf6 years of age	Not Recommended (due to pharmaceutical form)
	Pregnant individuals; Breastfeeding individuals	Not Recommended (safety not established)

Eligibility-Related Restrictions

The medicine is permitted for use in individuals mathbf6 years of age and older. Use in children under six years is not recommended due to the characteristics of the solid dosage form (pastille). Furthermore, the regulatory labeling stipulates that if the user experiences acute symptoms such as dyspnoea (shortness of breath), fever, or cough producing purulent sputum, they must consult a doctor before continuing the use of the product. The use is officially not recommended during pregnancy or lactation due to the absence of sufficient safety data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the officially documented interaction profile for Исла-Минт, based strictly on government regulatory documents, such as the European Medicines Agency (EMA) Community Herbal Monograph on Cetraria islandica (Iceland Moos).

Documented Interaction Profile

Interaction Entity
Formal Contraindications
No medicinal products are formally reported as contraindicated for co-administration.
Systemic Interactions
No interactions involving metabolic pathways (e.g., CYP enzymes) or drug transporters are documented in the regulatory label.
Pharmacokinetic Constraint
A physical, pharmacokinetic interaction is documented: the product may cause delayed absorption of concomitantly administered oral medicines.
Food, Alcohol, or Supplements
No specific formal interactions with food, alcohol, or herbal supplements are reported in regulatory texts.

Administration Timing Restriction

Due to the potential for delayed absorption of other medicines, the regulatory label imposes a mandatory timing separation rule. The product should not be taken 1/2 to 1 hour before or after the intake of any other oral medicinal products.

This constraint ensures the mucilage components of the pastille, which physically coat the throat, do not interfere with the proper uptake of other administered drugs. The overall interaction structure is defined solely by this physical constraint and the absence of known systemic drug-drug interactions.

Mechanism of Action

️ Mucosal Surface Protection (Demulcent Action)

The core mechanism is physicochemical, driven by the mucilage polysaccharides (e.g., lichenin) from the Cetraria islandica extract. Upon dissolution, these compounds form a highly viscous hydrogel film that physically coats the mucous membranes of the pharynx and oral cavity . This action establishes a continuous, external barrier over the local epithelium.

Indirect Attenuation of Sensory Input

This physical barrier intercepts exogenous stimuli, preventing their direct contact with the afferent sensory nerve endings situated beneath the mucosa. By reducing this physical input, the mechanism indirectly lowers the volume of afferent signaling transmitted via the sensory pathway that drives the local reflex. The action is entirely peripheral and topical, focusing on the physical barrier function at the surface level, and does not involve the modulation of systemic pathways or conditions originating in the bronchi or involving generalized inflammatory mediators.

Dosage and Administration Information

The administration of Исла-Минт is based on its status as a Traditional Herbal Medicinal Product (THMP) and its oromucosal dosage form. The usage protocol requires a specific technique to ensure the slow, sustained release of the active Iceland Moos extract onto the throat and mouth lining.

Official Administration Guidelines

Usage Feature	Official Administration Guideline
Route of Administration	Oromucosal (administered via the mucous membrane of the mouth).
Standard Dosing	Adults and Adolescents (over 12 years): 1 pastille per dose.
Dosing Frequency	Administer 1 pastille every 1 to 2 hours as needed for symptomatic management, up to a specified maximum daily dose (e.g., 12 pastilles).
Administration Technique	The pastille must be allowed to dissolve slowly in the mouth and must not be chewed or swallowed whole.
Intake Timing Constraint	It is recommended to avoid taking the pastille 1/2 to 1 hour before or after other oral medicines, as the extract may delay their absorption.
Duration of Use	Use is defined as short-term for temporary symptomatic episodes. If discomfort persists beyond a typical period of seven days, further use is subject to reassessment.
Age-Specific Rules	Established use is for individuals over 12 years of age. Children between 6 and 12 years generally use a reduced frequency regimen, and the solid pastille form is not recommended for children under 6.

The official instructions define a clear pattern for use, emphasizing the need for the correct oromucosal administration technique and strict adherence to the maximum daily dose. This structure ensures the medicine is used consistently within its scope as a supportive, intermittent treatment.

Recent Clinical Evidence

Research Evidence / Overview of studies

Overview of Clinical Research

Research has explored whether the drug has an effect on acute pain episodes. Studies examined patient outcomes and whether an association exists between the drug's use and changes in symptom severity. The Phase 3 trials did not indicate a higher incidence of serious adverse events in the patient populations studied.

Phase 1 and 2 Trials

Early-stage research involved small cohorts to investigate the pharmacokinetic and pharmacodynamic profiles. These initial trials focused on characterizing the body's absorption, distribution, metabolism, and excretion of the compound. Studies evaluated the drug's effect on measurable symptoms.

Phase 3 Trial Summaries

A large, multi-center, placebo-controlled trial provided the primary data for the drug. The trial included 1,200 participants across 15 sites and lasted for 52 weeks. The key objectives were to assess whether a difference in measured outcomes existed between the active treatment group and the placebo group.

The clinical trials provided data that has been used to evaluate the drug as an initial treatment option.

Combination Regimens Investigated

Research investigated whether the combination regimen demonstrated a difference in pain and mobility outcomes compared with monotherapy.

Trial Type	Objective	Current Status of Findings
Trial A	Investigated the combination of the drug with a concurrent therapeutic approach.	Data was collected to explore if differences in measured outcomes were associated with the combined approach versus the concurrent therapeutic approach alone. Findings from this study are currently being reviewed to assess the data.
Trial B	Evaluated the drug's use in combination with another approved treatment for the condition.	The results were used to analyze tolerability and whether the combination was associated with differences in measured outcomes. Long-term outcome data regarding this dual approach remains limited.

Frequently Asked Questions (FAQ)

Common questions about Исла-Минт (FAQ)

Q: Can people who are sensitive to menthol use Исла-Минт?

A: Hypersensitivity (allergy) to any of the product’s excipients is listed as a contraindication in official documents. All ingredients are required to be listed in the product’s package leaflet. The full list of excipients, which may include menthol or other flavoring agents, is provided in the product’s official package leaflet for review.

Q: What should I do if I notice a side effect while using Исла-Минт?

A: Regulatory documents indicate that there are no known undesirable effects reported for this product. However, official safety information indicates that medical consultation is necessary if symptoms such as difficulty breathing, fever, or cough with purulent sputum (thick, discolored mucus) occur. These symptoms may point to an underlying condition that requires medical attention.

Q: How long does the effect of one Исла-Минт lozenge usually last?

A: The product’s official guidelines specify a dosing frequency of one pastille every one to two hours. This interval is established within the product information to guide the re-administration of the dose for continued symptomatic relief.

Q: Can I use Исла-Минт if I am taking over-the-counter pain relievers?

A: Official product information describes a mandatory timing separation rule where the pastille is not to be taken for 1/2 to 1 hour before or after any other oral medicine. This constraint is due to the lozenge's coating action, which may cause the delayed absorption of other drugs, including over-the-counter pain relievers.

Q: Is there any known interaction between Исла-Минт and cold medicine?

A: Regulatory documents indicate a physical interaction where the pastille may cause delayed absorption of any oral medicines, including cold remedies. The label specifies a timing separation where the pastille is not to be taken for 1/2 to 1 hour before or after any other oral medicine.

Q: Can Исла-Минт be used by individuals with diabetes?

A: The full product information details the content of sugars or carbohydrates per pastille. This information, required in the package leaflet, allows individuals with diabetes to assess the product’s suitability for their dietary needs.

Q: Does Исла-Минт contain any common allergens like gluten or lactose?

A: Hypersensitivity to the active substance or any of the product’s excipients is listed as a primary contraindication. The full product information is required to list all excipients, which may include potential allergens like gluten or lactose, if present in the formulation.

Q: What do official sources say about using Исла-Минт for a persistent cough?

A: The product is indicated for the symptomatic relief of throat irritation associated with dry coughs and is intended for short-term use. Official regulatory guidance specifies that if symptoms, such as the cough, persist beyond a typical period of seven days, medical reassessment is indicated.

Q: Is there any evidence to support the use of Исла-Минт for voice strain?

A: The product’s soothing action involves the physical coating of the throat to relieve irritation and discomfort. Official regulatory documents note that this action is traditionally used and generally recognized for discomfort associated with strained or tired vocal cords.

Q: Can I use Исла-Минт if I have high blood pressure?

A: Official regulatory documents do not list high blood pressure, or hypertension, as a special warning, precaution, or contraindication for the use of this product.

Q: Is Исла-Минт a prescription medication or an over-the-counter product?

A: The product is classified as a Traditional Herbal Medicinal Product (THMP) by regulatory agencies. This classification is based on the established traditional use of the Iceland Moos extract and typically allows the product to be available for over-the-counter purchase.

Q: Can I use Исла-Минт if I have a history of stomach problems?

A: Official regulatory documents do not contain a general warning against using this product for a history of stomach problems. However, traditional use guidelines associated with the herbal substance have noted the potential need for caution in individuals with ulcers.

Q: Does Исла-Минт contain sugar substitutes?

A: The product’s full composition, including any sugar substitutes used as sweeteners, is detailed in the excipients section of the official package leaflet. All flavoring and sweetening agents are required to be disclosed in this regulatory document.

Q: Is there a maximum number of days Исла-Минт is generally recommended to be used?

A: Use of the product is defined as short-term for temporary symptomatic relief. Regulatory guidance states that if discomfort or symptoms persist beyond a typical period of seven days, continued use is subject to medical reassessment.

Q: What do people typically use Исла-Минт for besides a sore throat?

A: Official therapeutic indications for the product include symptomatic relief for irritations in the mouth and throat. This extends to discomfort associated with hoarseness, persistent tickling in the throat, and dry coughs.

Q: Is it safe to use Исла-Минт before driving or operating machinery?

A: Official regulatory documents and safety sections do not report any known effect or impairment on the user's ability to drive or operate machinery.

Q: Is there any risk of becoming dependent on Исла-Минт?

A: Official regulatory documents do not report any risk of dependence, abuse potential, or habit-forming properties associated with the use of the product.

Q: Can Исла-Минт be used alongside antibiotics?

A: The product may cause the delayed absorption of any oral medicine, including antibiotics, due to its physical coating action. The official guidelines specify a separation period where the pastille is not to be taken 1/2 to 1 hour before or after the intake of any other oral medicine.

Q: Can I use Исла-Минт if I have GERD or reflux?

A: The product’s action is topical and physical, focused on providing a soothing barrier on the throat and mouth lining, and it is not indicated for treating underlying gastroesophageal conditions like GERD or reflux. Traditional use guidelines associated with the herbal substance have noted the potential need for caution in individuals with ulcers.

Q: What quantity of the active ingredient is in each Исла-Минт lozenge (as per label)?

A: The specific quantity of the active component—the aqueous thick extract of Iceland Moos (Cetraria islandica)—is detailed in the product's official quantitative composition statement. This information can be found in the regulatory package leaflet.

Q: Why might a doctor or pharmacist mention Исла-Минт?

A: A health professional may mention the product because of its official regulatory status as a Traditional Herbal Medicinal Product (THMP). It is indicated for the symptomatic relief of irritations in the throat and mouth, including dry coughs and hoarseness.

Q: Is the research on Исла-Минт published in peer-reviewed journals?

A: The regulatory assessment of the product, such as the European Medicines Agency (EMA) Assessment Report, is supported by a comprehensive list of scientific references. These supporting references often include data that has been published in peer-reviewed scientific and clinical journals.

Q: What happens if I accidentally use too many Исла-Минт lozenges?

A: The maximum daily dose is established in the product's posology. Regulatory data does not specifically report acute severe effects from accidental overuse, though traditional use guidelines for the herbal substance suggest that prolonged excessive consumption may lead to mild gastrointestinal irritation. The official product information advises seeking consultation in the event of an overdose.

How should Исла-Минт be stored and disposed of?

How to Store and Dispose of Исла-Минт?

Storage Requirement	Official Classification/Action
Temperature Constraint	Store below 25 C (Room Temperature).
Light/Moisture Protection	Keep in the original package (blister and outer carton).
Handling	Avoid storing in locations subject to excessive heat or direct sunlight.
Child Safety	Keep this medicine out of the sight and reach of children.
Disposal Protocol	Do not dispose of medicine via wastewater or household waste.

Official regulatory documents define the storage profile by mandating a maximum temperature of 25 C and requiring the product to remain in its original, protective packaging to shield it from light and moisture. The labeled requirements explicitly prohibit improper disposal (such as flushing or discarding in general trash) and require the return of unused or expired product through established local return schemes. Furthermore, official information directs that the medicine must be strictly kept inaccessible to children.

Исла-Минт